TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06286020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
Study: NCT06070753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
Study: NCT05455086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking
Description: Receive 1 puff of tobacco flavored protonated e-liquid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette Smoking
Description: Receive 1 puff of unflavored protonated e-liquid

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking
Description: Receive 1 puff of unflavored protonated e-liquid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette Smoking
Description: Receive 1 puff of tobacco flavored unprotonated cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking
Description: Receive 1 puff of tobacco flavored unprotonated cigarette

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette Smoking
Description: Receive 1 puff of unfavored unprotonated cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking
Description: Receive 1 puff of unfavored unprotonated cigarette

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06485648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Description: Treatment: G(glucocorticoid) + i.v. uc-MSC (1×106 cells/Kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Control: G(glucocorticoid) + i.v. Normal saline
Study: NCT05549947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1819
Description: Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1819
Description: Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1819
Description: Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group D：placebo
Study: NCT05910892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy packet
Description: 5 deep breaths from packet prior to treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo packet
Description: 5 deep breaths from packet prior to treatment
Study: NCT05928949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pilates exercises
Description: Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercises
Description: Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
Study: NCT05521152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine Bitartrate
Description: anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.~the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04971083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
Study: NCT05837793

Intervention type: BEHAVIORAL
Intervention: Modified frailty index
Description: The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.

Intervention type: BEHAVIORAL
Intervention: Modified frailty index
Description: The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
Study: NCT05610579

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remedial exercise
Description: Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remedial exercise
Description: Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandage
Description: Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions with compression bandage. The bandage will be removed at the same time the next day. Patients will be monitored telephonically in the washout period for remain the routine activities.
Study: NCT05569993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: .3 mg/kg of glutamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placcebo
Description: Patients will recieve placcebo
Study: NCT06266520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MNK therapy to release the superficial fascia
Description: The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Acupuncture treatment employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm\*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm\*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
Study: NCT05887024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock wave Therapy
Description: Shock wave therapy: (BECO) S/N 16B011375

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: EME (Therapic 9400) TENS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: EME (Therapic 9400) TENS

Intervention type: PROCEDURE
Group type: OTHER
Intervention: McKenzie Back exercises
Description: Graduated Progressive back exercise program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie Back exercises
Description: Graduated Progressive back exercise program.
Study: NCT05887739

Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial gait analysis
Description: All groups will be evaluated with inertial gait analysis
Study: NCT05887024

Intervention type: DEVICE
Group type: OTHER
Intervention: electric heating pads
Description: electrical conducting heat pack.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electric heating pads
Description: electrical conducting heat pack.
Study: NCT05940766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated fever alerts
Description: Fever alerts are automated sent to participants if fever is detected
Study: NCT05290077

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NGAL
Description: Serum NGAL in blood for early detection of CVR

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NGAL
Description: Serum NGAL in blood for early detection of CVR
Study: NCT06207760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
Study: NCT05480553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-06
Description: 1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds.
Study: NCT05559372

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acute energy drink or placebo consumption
Description: Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute energy drink or placebo consumption
Description: Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute energy drink or placebo consumption
Description: Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
Study: NCT04856631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: 240mg once per 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Solution for infusion
Description: First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
Study: NCT04490018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)
Description: Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)
Description: Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group A, C, W-135, and Y conjugate vaccine
Description: Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 9-valent Vaccine (9vHPV)
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus 9-valent Vaccine (9vHPV)
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 9-valent Vaccine (9vHPV)
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT05073861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEM learning
Description: Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEM learning
Description: Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge.
Study: NCT06366698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer 200 MG Per 10 ML Injection
Description: 200 mg IV every 2 days until the targeted dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous sulfate
Description: Take 1 tablet every other day with lemon/orange juice
Study: NCT04334889

Intervention type: OTHER
Intervention: Visual cues
Description: Participants will be asked to move following cues displayed on a screen in front of them.

Intervention type: OTHER
Intervention: Visual cues
Description: Participants will be asked to move following cues displayed on a screen in front of them.
Study: NCT05351489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
Study: NCT06262178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting-STAIR
Description: 10-15 week Parenting-STAIR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Will include either Prolonged Exposure or Cognitive Processing Therapy